222 related articles for article (PubMed ID: 20551053)
21. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
22. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
23. Analysis of PIK3CA mutations in breast cancer subtypes.
Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
[TBL] [Abstract][Full Text] [Related]
24. Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma.
Lubin D; Toorens E; Zhang PJ; Jaffer S; Baraban E; Bleiweiss IJ; Nayak A
Am J Surg Pathol; 2019 Jul; 43(7):1005-1013. PubMed ID: 31094929
[TBL] [Abstract][Full Text] [Related]
25. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
26. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Wu G; Xing M; Mambo E; Huang X; Liu J; Guo Z; Chatterjee A; Goldenberg D; Gollin SM; Sukumar S; Trink B; Sidransky D
Breast Cancer Res; 2005; 7(5):R609-16. PubMed ID: 16168105
[TBL] [Abstract][Full Text] [Related]
28. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
29. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
Dupont Jensen J; Laenkholm AV; Knoop A; Ewertz M; Bandaru R; Liu W; Hackl W; Barrett JC; Gardner H
Clin Cancer Res; 2011 Feb; 17(4):667-77. PubMed ID: 20940279
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
34. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
[TBL] [Abstract][Full Text] [Related]
35. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
Lerma E; Catasus L; Gallardo A; Peiro G; Alonso C; Aranda I; Barnadas A; Prat J
Virchows Arch; 2008 Aug; 453(2):133-9. PubMed ID: 18679714
[TBL] [Abstract][Full Text] [Related]
36. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
37. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic PIK3CA mutations in lobular breast cancer progression.
Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
[TBL] [Abstract][Full Text] [Related]
39. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
40. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
